Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients

Purpose: Bone is the most common metastatic site for prostate cancer, and osseous metastases are the leading cause of morbidity from this disease. Recent autopsy studies prove that 100% of men who die of prostate cancer have bone involvement. Understanding the biology of prostate cancer and its evolution to an incurable androgen-independent phenotype requires an understanding of the genetic and cellular alterations that lead to the seeding and proliferation of tumor foci in bone, as well as the microenvironment in which these metastases arise. No intensive studies, however, have been conducted on osseous metastatic tissues from patients with metastatic prostate cancer due to lack of access to such tissues for profiling and other research. Experimental Design: We show, for the first time, a reproducible methodology to obtain high quality clinical tumor tissues metastatic to the bone. This technique allowed the procurement of viable metastatic tumor tissue from involved bones in 13 recent autopsies conducted at the University of Michigan and analyzed the gene expression of these tissues using real-time PCR and microarrays. Results: We present here the discovery of nonossified bone metastases from multiple patients with advanced prostate cancer and their subsequent characterization and comparison to nonosseous metastases from the same patients. Conclusion: This represents a versatile and practical approach that may be employed to characterize the steps in metastasis and the phenotypic characteristics of osseous metastasis of prostate cancer and to profile RNA, DNA, and cDNA from tumor samples metastatic to the bone. Clin Cancer Res; 17(12); 3924–32. ©2011 AACR.

[1]  Rakesh Kumar,et al.  MicroRNAs and cancer therapy: The next wave or here to stay? , 2010, Cancer biology & therapy.

[2]  J. Cheville,et al.  USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 , 2010, Cell.

[3]  D. Katsaros,et al.  Down-regulation of dicer expression in ovarian cancer tissues. , 2010, Clinical biochemistry.

[4]  Michael T. McManus,et al.  Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. , 2009, Gastroenterology.

[5]  B. Klein,et al.  MMSET is overexpressed in cancers: link with tumor aggressiveness. , 2009, Biochemical and biophysical research communications.

[6]  Sabine Riethdorf,et al.  Circulating Tumor Cells and Bone Marrow Micrometastasis , 2008, Clinical Cancer Research.

[7]  E. Keller,et al.  Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. , 2008, Cancer research.

[8]  R. Shah,et al.  CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER , 2008 .

[9]  F. Gao,et al.  Decreased expression of DICER1 in gastric cancer. , 2007, Chinese medical journal.

[10]  A. Vincent-Salomon,et al.  Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues , 2007, Journal of Clinical Pathology.

[11]  W. Jiang,et al.  Bone morphogenetic proteins and their receptor signaling in prostate cancer. , 2007, Histology and histopathology.

[12]  K. Pienta,et al.  The evolving biology and treatment of prostate cancer. , 2007, The Journal of clinical investigation.

[13]  I. Christensen,et al.  Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival , 2007, Clinical Cancer Research.

[14]  Rajiv Dhir,et al.  Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. , 2006, The American journal of pathology.

[15]  K. Pienta,et al.  CCL2 is a potent regulator of prostate cancer cell migration and proliferation. , 2006, Neoplasia.

[16]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[17]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[18]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[19]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Hubert Vesselle,et al.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. , 2003, Human pathology.

[21]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[22]  Debashis Ghosh,et al.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.

[23]  J. Pinski,et al.  Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. , 2001, Cancer research.

[24]  J. Maier,et al.  Modulation of WHSC2 expression in human endothelial cells , 2000, FEBS letters.

[25]  K. Pienta,et al.  Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  P. L. Bergsagel,et al.  The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3 and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid Transcripts , 1998 .

[27]  A. Rywlin,et al.  Metastatic carcinoma in histologic sections of aspirated bone marrow: a comparative autopsy study. , 1976, Southern medical journal.

[28]  P. L. Bergsagel,et al.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.